Annelore Cortoos

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Peter M. Voorhees, Douglas W. Sborov, Jacob P. Laubach et al. · The Lancet Haematology · 2023 · 153 citations

Medicine, Pharmacology, Pharmacotherapy +16

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Meletios Α. Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold et al. · New England Journal of Medicine · 2024 · 94 citations

Medicine, Hematology, Pharmacotherapy +15

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Alì Taher, Raffaella Origa, Silverio Perrotta et al. · American Journal of Hematology · 2017 · 78 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

Saurabh Chhabra, Natalie S. Callander, Nicole Watts et al. · Transplantation and Cellular Therapy · 2022 · 59 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Ashraf Badros, Laahn Foster, Larry D. Anderson et al. · Blood · 2024 · 50 citations · Full text

Medicine, Oncology, Pharmacotherapy +14